STAT+: Amgen wins FDA approval for first KRAS-blocking lung cancer drug
The Food and Drug Administration on Friday approved the first drug that benefits patients with lung cancer caused by a specific genetic mutation to a protein called KRAS, a target that for decades was considered to be “undruggable.”
The new medicine, a pill called Lumakras, was developed by Amgen.
Continue to STAT+ to read the full story…
Read Original Article: STAT+: Amgen wins FDA approval for first KRAS-blocking lung cancer drug »
